Literature DB >> 19371812

Alternative indications for bisphosphonate therapy.

Regina Landesberg1, Sidney Eisig, Ilene Fennoy, Ethel Siris.   

Abstract

Bisphosphonates are currently used in the treatment of osteoporosis (postmenopausal and steroid-induced), hypercalcemia of malignancy, Paget's disease of bone, multiple myeloma, and skeletally related events associated with metastatic bone disease in breast, prostate, lung, and other cancers. There are, however, numerous other conditions where a decrease in bone remodeling by bisphosphonates might aid in disease management. The focus of this review will be to discuss a select group of conditions for which bisphosphonate therapy may be efficacious. In this review we present several cases where bisphosphonates have been used as a primary or adjunctive treatment for giant cell lesions of the jaws. Use of bisphosphonate therapy for giant cell tumors of the appendicular skeleton, pediatric osteogenesis imperfecta, fibrous dysplasia, Gaucher's disease, and osteomyelitis will be discussed. Finally, we will review previous in vivo studies on the use of bisphosphonates to augment integration and to treat osteolysis surrounding failing orthopedic implants.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19371812     DOI: 10.1016/j.joms.2008.12.006

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  9 in total

Review 1.  The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.

Authors:  Samantha Pozzi; Noopur Raje
Journal:  Oncologist       Date:  2011-04-14

2.  Role of polyethylene particles in peri-prosthetic osteolysis: A review.

Authors:  Gerald J Atkins; David R Haynes; Donald W Howie; David M Findlay
Journal:  World J Orthop       Date:  2011-10-18

3.  An unusual case of atrophic mandible fracture in a patient with osteogenesis imperfecta and on oral bisphosphonate therapy: Case report.

Authors:  Abdulrahman Al-Osaimi; Mahmood Samman; Mohammad Al-Shakhs; Faisal Al-Suhaim; Sundar Ramalingam
Journal:  Saudi Dent J       Date:  2014-03-12

4.  Clinical and Radiologic Response of Central Giant Cell Granuloma to Denosumab: A 6-Year Prospective Observational Study.

Authors:  Yoon Ji Jina Rhou; Che-Jen Wang; Minh Nguyen; Joel A Vanderniet; Craig F Munns; Hedley Coleman; James Kim; Deborah Jane Holmes-Walker; Lydia Lim; Christian M Girgis
Journal:  Calcif Tissue Int       Date:  2022-01-28       Impact factor: 4.333

Review 5.  Aggressive giant cell granuloma of the jaws treated with interferon alpha: a report of two cases.

Authors:  J E O'Connell; G J Kearns
Journal:  Ir J Med Sci       Date:  2012-10-26       Impact factor: 1.568

Review 6.  Effect of adjuvant bisphosphonates on treatment of periodontitis: Systematic review with meta-analyses.

Authors:  Francisco Wilker Mustafa Gomes Muniz; Bernardo Franco da Silva; Conrado Richel Goulart; Taciane Menezes da Silveira; Thiago Marchi Martins
Journal:  J Oral Biol Craniofac Res       Date:  2021-01-21

7.  The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis.

Authors:  Yan-Li Yang; Zi-Jian Xiang; Jing-Hua Yang; Wen-Jie Wang; Ruo-Lan Xiang
Journal:  Ther Adv Med Oncol       Date:  2019-06-09       Impact factor: 8.168

8.  Bioinformatic Data Mining for Candidate Drugs Affecting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) in Cancer Patients.

Authors:  Jinpeng Zhuang; Jianing Zu; Changlong Zhou; Yi Sun; Pengyu Kong; Yongbin Jing
Journal:  Dis Markers       Date:  2022-09-14       Impact factor: 3.464

9.  Treatment of central giant cell lesions using bisphosphonates with intralesional corticosteroid injections.

Authors:  Newton Guerreiro Júnior da Silva; Aline Semblano Dias Carreira; Erick Nelo Pedreira; Fabrício Mesquita Tuji; Karem López Ortega; João de Jesus Viana Pinheiro
Journal:  Head Face Med       Date:  2012-08-22       Impact factor: 2.151

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.